Lipid-Linked CpG Amphiphiles for Lymph Node Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective cancer treatments, particularly for HPV-related cancers, as they are among the fastest growing cancers globally, and existing treatments are inadequate.
Innovation Solution
Development of compounds comprising CpG oligodeoxynucleotides linked to lipids or lipid salts, which are administered with HPV proteins to induce an immune response against HPV-positive cancer cells, optionally combined with platinum-containing chemotherapy and anti-PD-1 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then treatment is provided, but effectiveness is insufficient for HPV-related cancers
Solution Approach 1:
The patent uses composite materials by combining CpG oligodeoxynucleotides with lipid moieties to create amphiphilic compounds. This composite structure enables the molecule to interact with both aqueous and lipid environments, facilitating enhanced delivery to lymph nodes and improving immune stimulation effectiveness against HPV-related cancers
Solution Approach 2:
The patent modifies chemical parameters by creating derivatives with different lipid attachments (varying chain lengths, saturation, and positions) on the CpG oligodeoxynucleotide backbone. These parameter changes optimize the compound's pharmacokinetic properties, stability, and immunogenicity, leading to improved treatment effectiveness
2Reliability
If CpG oligodeoxynucleotides are linked to lipid moieties, then delivery to lymph nodes is enhanced, but molecular complexity increases
Solution Approach 1:
The lipid moiety acts as an intermediary that facilitates the interaction between the hydrophobic cellular membranes and the hydrophilic CpG oligodeoxynucleotide. This intermediary structure enables the compound to traverse biological barriers and reach lymph nodes effectively, while the modular design allows for systematic variation of lipid components
Solution Approach 2:
The molecule is segmented into distinct functional domains: the CpG oligodeoxynucleotide portion that provides immunostimulatory activity and the lipid portion that provides membrane interaction and delivery enhancement. This segmentation allows independent optimization of each domain's function while maintaining overall molecular stability
Data Source
AI summary
The invention provides compounds including a CpG oligodeoxynucleotide sequence linked to a lipid by a linker and related compositions and methods. The invention features a compound consisting of the nucleotide sequence of SEQ ID NO:1, at its 5′ end, bonded or linked by a linker to a lipid. Further, the invention features a method of treating a cancer in a human patient, comprising administering to the patient the compound. Further, the invention features a pharmaceutical composition including the compound and a pharmaceutically acceptable carrier. The invention features a kit including (I) the compound or a composition comprising the compound; and (ii) a protein comprising SEQ ID NO:2 or SEQ ID NO:3.